A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases

Clinical Cancer Research

Volumn 12, Issue 5, 2006, Pages 1556-1563

  Lara Jr , Primo N ^a,f   Stadler, Walter M ^e   Longmate, Jeff ^d   Quinn, David I ^c   Wexler, Jason ^a   Van Loan, Marta ^b   Twardowski, Przemyslaw ^d   Gumerlock, Paul H ^a   Vogelzang, Nicholas J ^e   Vokes, Everett E ^e   Lenz, Heinz Josef ^c   Doroshow, James H ^d   Gandara, David R ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b U S DEPARTMENT OF AGRICULTURE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Veterans Administration of Northern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; HEMOGLOBIN; MATRIX METALLOPROTEINASE INHIBITOR; OSTEOCALCIN; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROSTATE SPECIFIC ANTIGEN; PYRIDINOLINE; REBIMASTAT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTHRITIS; ARTICLE; BONE METABOLISM; BONE METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SURVIVAL TIME; THROMBOSIS;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33645080175     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2074     Document Type: Article

References (27)

1. Jemal A, Curry T, Ward E, et al. Cancer statistics 2005: CA Cancer J Clin 2005;55:10-30.
2. Catalona W. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
3. Petrylak DP, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
4. Tannock I, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
5. Rizvi N, Humphrey JS, Neww EA, et al. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004;10:1963-70.
6. Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17-25.
7. Sehgal G, Hua J, Bernhard EJ, et al. Requirement for matrix metalloproteinase 9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 1998;152:591-6.
8. Pollen JJ, Gerber K, Ashburn W, et al. Nuclear bone imaging in metastatic cancer of the prostate. Cancer 1981;47:2585.
9. Maeda H, Koizumi M, Yoshimura K, et al. Correlation between bone metabolic markers and bone scan in prostate cancer. J Urol 1997;157:539-43.
10. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer 2000;88:2952-60.
11. Ali SM, Demers LM, Leitzel K, et al. Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 2004;15:455-9.
12. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
13. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13.
14. Glaves D. Mechanisms of metastasis: prostate cancer. Prog Clin Biol Res 1987;239:329-45.
15. Demers LM. Bone markers in the management of patients with skeletal metastases. Cancer 2003;97:874-9.
16. Conway JG, Trexler SJ, Wakefield JA, et al. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin Exp Metastasis 1996;14:115-24.
17. Thompson DD, Seedor JG, Fisher JE, et al. Direct action of the parathyroid hormone-like human hypercalcemic factor on bone. Proc Natl Acad Sci U S A 1988;85:5673-7.
18. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 Suppl:S42-51.
19. Wood M, Fudge K, Mohler JL, et al. In situ hybridization studies of metalloproteinases 2 and 9 an dTIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-58.
20. Berruti A, Piovesan A, Torta M, et al. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiographic appearances and disease extension. Br J Cancer 1996;73:1581-7.
21. Takeuchi S, Saitoh H. Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma. Int J Urol 1997;4:368-73.
22. Takeuchi S, Arai K, Saitoh H, et al. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol 1996;156:1691-5.
23. Blomqvist C, Risteli L, Risteli J, et al. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996;73:1074-9.
24. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
25. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Clin Orthop 2003:138-47.
26. Parisi MS, Oliveri B, Mautalen CA. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 2003;33:582-8.
27. Miller KD, Saphner TJ, Waterhouse DM, et al. A randomized phase II feasibility trial of BMS275291 in patients with early stage breast cancer. Clin Cancer Res 2004;10:1971-5.